Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2015 | Image of the Month

In vivo visualization of prostate-specific membrane antigen in glioblastoma

Authors: Johannes Schwenck, Ghazaleh Tabatabai, Marco Skardelly, Gerhald Reischl, Rudi Beschorner, Bernd Pichler, Christian la Fougère

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2015

Excerpt

The expansion of nutrient vessels is an important factor in the growth of glioblastomas (GBM), which is one of the most vascularized tumours [1]. Therefore, new treatment concepts that include tumour vasculature targets are currently under investigation. Prostate-specific membrane antigen (PSMA) is overexpressed in the tumour vasculature of GBM, which therefore might be considered as a potential endothelial target for treatment with PSMA-based agents [2, 3]. However, according to the limited data so far available, PSMA expression in brain tumours varies with glioma grade [4]. …

Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005;5:436–46. doi:10.1038/nrc1627.PubMedCrossRef

Wernicke AG, Edgar MA, Lavi E, Liu H, Salerno P, Bander NH, et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med. 2011;135:1486–9. doi:10.5858/arpa.2010-0740-OA.PubMedCrossRef

Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91. doi:10.1158/1078-0432.CCR-13-0231.PubMedCentralPubMedCrossRef

Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int. 2014;14:26. doi:10.1186/1475-2867-14-26.PubMedCentralPubMedCrossRef

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20. doi:10.1007/s00259-013-2525-5.PubMedCentralPubMedCrossRef

Title: In vivo visualization of prostate-specific membrane antigen in glioblastoma
Authors: Johannes Schwenck
Ghazaleh Tabatabai
Marco Skardelly
Gerhald Reischl
Rudi Beschorner
Bernd Pichler
Christian la Fougère
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2921-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

In vivo visualization of prostate-specific membrane antigen in glioblastoma

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

Liver SUV versus stage in Hodgkin’s lymphoma: the total amount of uptake may play a role in the inverse relationship

Diagnostic accuracy and impact on management of 18F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review

Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology

Athanasios D. Gouliamos, John A. Andreou and Paris A. Kosmidis (Eds): Imaging in Clinical Oncology

68Ga-DOTA0-Tyr3-octreotide positron emission tomography in nasopharyngeal carcinoma

Comparison of in vivo binding properties of the 18-kDa translocator protein (TSPO) ligands [18F]PBR102 and [18F]PBR111 in a model of excitotoxin-induced neuroinflammation